Stephen Juvet, Gregory I. Snell, Saskia Bos, Marie M. Budev, John R. Greenland, Kieran Halloran, Sandra Lindstedt, Laurie D. Snyder, Rayid Abdulqawi, Atefeh Abedini, Selim M. Arcasoy, Meghan Aversa, Alberto Benazzo, Daniel R. Calabrese, Fiorella Calabrese, Marlene Cano, Kevin Chan, Satish Chandrashekaran, D. Darley, Amir Emtiazjoo, Tara Fallah, Laurent Godinas, René Hage, Jr. Don Hayes, Howard J. Huang, Jana Kleinerová, Sakhee Kotecha, Akshay Kumar, Francesca Lunardi, Jorge Mallea, Tereza Martinu, Federica Meloni, Anoop Mohandas, Eric D. Morrell, Arun Nair, Rene Novysedlak, Michael Perch, Federica Pezzuto, Clement Picard, Peter Riddell, Anja C. Roden, Justin P. Rosenheck, Julie Semenchuk, Unmil Shah, Heather Strah, Laneshia K Tague, Rade Tomic, Anil J. Trindade, Katherine Vandervest, Geert M. Verleden, Glen Westall, Ciara M. Shaver
Chronic Lung Allograft Dysfunction (CLAD) is the major barrier to long-term survival post-lung transplantation and is defined primarily by spirometric assessment. However, because substantial and potentially irreversible pathology may develop before the diagnostic criteria for CLAD are met, it is critical to identify lung transplant recipients at high risk for lung function decline that might benefit from early therapeutic interventions to reverse ongoing injury. Equally, CLAD progression may result from similar acute insults after the diagnosis of CLAD is established.